Adaptive Biotechnologies Revenue Growth Rates (ADPT), Current and Historic Growth - CSIMarket
CSIMarket Company Name, Ticker, Suppliers, else..
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Sales Y/Y Annual
Adaptive Biotechnologies Corporation  (NASDAQ: ADPT)
 

ADPT's Revenue Growth by Quarter and Year

Adaptive Biotechnologies's Revenue results by quarter and year



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

ADPT Revenue (in millions $) FY 2026 FY 2025 FY 2024 FY 2023
4th Quarter December -
3rd Quarter September -
2nd Quarter June 71.55
1st Quarter March 70.87
FY 142.42

ADPTs Annual Revenue
Adaptive Biotechnologies's Revenue in the fiscal year 2025 $ 276.98 millions
Adaptive Biotechnologies's Revenue in the fiscal year 2024 $ 178.96 millions
Adaptive Biotechnologies's Revenue in the fiscal year 2023 $ 170.28 millions
Adaptive Biotechnologies's Revenue in the fiscal year 2022 $ 185.31 millions
Adaptive Biotechnologies's Revenue in the fiscal year 2021 $ 154.34 millions




ADPT Revenue second quarter 2026 Y/Y Growth Comment
Adaptive Biotechnologies Corporation reported Revenue improvement of 21.52% year on year in the second quarter 2026, to $ 71.55 millions, this is lower than Adaptive Biotechnologies Corporation's recent average Revenue rise of 48.79%.

Looking into second quarter 2026 results within Biotechnology & Pharmaceuticals industry 29 other companies have achieved higher Revenue growth. While Adaptive Biotechnologies Corporation' s Revenue rise of 21.52% ranks overall at the positon no. 978 in the second quarter 2026.


ADPT Revenue ( Y/Y Growth %) 2026
 2025 2024 2023
4th Quarter December - 51.03 % 3.67 % -17.07 %
3rd Quarter September - 102.35 % 22.47 % -20.72 %
2nd Quarter June 21.52 % 36.33 % -11.73 % 12.07 %
1st Quarter March 35.14 % 25.24 % 11.21 % -2.51 %
FY   - 54.77 % 5.1 % -

Financial Statements
Adaptive Biotechnologies's second quarter 2026 Revenue $ 71.55 millions ADPT's Income Statement
Adaptive Biotechnologies's second quarter 2025 Revenue $ 58.88 millions Quarterly ADPT's Income Statement


ADPT Revenue (Quarter on Quarter Growth %)

 2026
 2025 2024 2023
4th Quarter December - -23.72 % 2.2 % 20.73 %
3rd Quarter September - 59.6 % 7.52 % -22.5 %
2nd Quarter June 0.96 % 12.28 % 3.15 % 29.96 %
1st Quarter March -1.13 % 10.49 % -8.54 % -31.79 %
FY (Year on Year)   - 54.77 % 5.1 % -


Back to ADPT Growth rate Comparisons >> Back to ADPT Growth rate Comparisons >>


Revenue second quarter 2026 Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #30
Healthcare Sector #196
Overall #978

Revenue Y/Y Growth Statistics
High Average Low
425.16 % 48.79 % -28.94 %
(Dec 31 2020)   (Sep 30 2020)
Revenue second quarter 2026 Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #30
Healthcare Sector #196
Overall #978
Revenue Y/Y Growth Statistics
High Average Low
425.16 % 48.79 % -28.94 %
(Dec 31 2020)   (Sep 30 2020)

Revenue by Quarter for the Fiscal Years 2023, 2024, 2025, 2026

Adaptive Biotechnologies's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
148.02 % 12.76 % -43.55 %
(Jun 30 2014)  


ADPT's II. Quarter Q/Q Revenue Comment
Adaptive Biotechnologies Corporation achieved in the II. Quarter 2026 below company average Revenue growth of 0.96% quarter on quarter, to $ 71.55 millions.

Within Biotechnology & Pharmaceuticals industry 29 other companies have achieved higher Revenue quarter on quarter growth. While Adaptive Biotechnologies's Revenue growth quarter on quarter, overall rank is 1610.


Revenue Q/Q Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #30
Healthcare Sector #216
Overall #1610
Revenue Q/Q Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #30
Healthcare Sector #216
Overall #1610
Revenue Q/Q Growth Statistics
High Average Low
148.02 % 12.76 % -43.55 %
(Jun 30 2014)  


ADPT's II. Quarter Q/Q Revenue Comment
Adaptive Biotechnologies Corporation achieved in the II. Quarter 2026 below company average Revenue growth of 0.96% quarter on quarter, to $ 71.55 millions.

Within Biotechnology & Pharmaceuticals industry 29 other companies have achieved higher Revenue quarter on quarter growth. While Adaptive Biotechnologies's Revenue growth quarter on quarter, overall rank is 1610.


Adaptive Biotechnologies's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Jun 30 2026)		 12 Months Ending
(Mar 31 2026)		 12 Months Ending
(Dec 31 2025)		 12 Months Ending
(Sep 30 2025)		 12 Months Ending
(Jun 30 2025)
Cumulative Revenue 12 Months Ending $ 308.08 $ 295.41 $ 276.98 $ 252.75 $ 205.22
Y / Y Revenue Growth (TTM) 50.13 % 55.87 % 54.77 % 42.57 % 21.6 %
Year on Year Revenue Growth Overall Ranking # 775 # 1343 # 1204 # 2311 # 2694
Seqeuential Revenue Change (TTM) 4.29 % 6.65 % 9.58 % 23.16 % 8.28 %
Seq. Revenue Growth (TTM) Overall Ranking # 1667 # 1608 # 1555 # 1184 # 2299


Cumulative Revenue growth Comment
With the quarterly Revenue reported in the Jun 30 2026 period, Adaptive Biotechnologies's cumulative twelve months Revenue were $ 308 millions, company would post below average annual Revenue growth of 8.28% year on year, if the fiscal year would end at Jun 30 2026.
A slow-down in the Adaptive Biotechnologies's Revenue growth from the 70.87% growth in Mar 31 2026.

In the Healthcare sector 163 other companies have achieved higher trailing twelve month Revenue growth. While Total ranking has impoved so far to 775, from total ranking in previous quarter at 1343.

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry # 33
Healthcare Sector # 164
Overall # 775

Revenue TTM Y/Y Growth Statistics
High Average Low
695.39 %
 97.8 %
-74.75 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 33
Sector # 267
S&P 500 # 1667
Cumulative Revenue growth Comment
With the quarterly Revenue reported in the Jun 30 2026 period, Adaptive Biotechnologies's cumulative twelve months Revenue were $ 308 millions, company would post below average annual Revenue growth of -74.75% year on year, if the fiscal year would end at Jun 30 2026.
A slow-down in the Adaptive Biotechnologies's Revenue growth from the 70.87% growth in Mar 31 2026.

In the Healthcare sector 163 other companies have achieved higher trailing twelve month Revenue growth. While Total ranking has impoved so far to 775, from total ranking in previous quarter at 1343.


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry # 33
Healthcare Sector # 164
Overall # 775

Revenue TTM Y/Y Growth Statistics
High Average Low
695.39 %
97.8 %
-74.75 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 33
Sector # 267
S&P 500 # 1667




Other Revenue Growth
Biotechnology & Pharmaceuticals Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
ADPT's Revenue Growth Ratio versus Biotechnology & Pharmaceuticals Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth




Companies with similar Revenue growth for the quarter ending Jun 30 2026 within Healthcare SectorY/Y Change %Revenue for the quarter ending Jun 30 2026
Zomedica Corp 36.59%$ 36.588 millions
Kura Oncology Inc 36.54%$ 36.538 millions
Scientific Industries Inc 36.02%$ 36.022 millions
Ceribell Inc 35.85%$ 35.852 millions
Intelligent Bio Solutions Inc 35.78%$ 35.777 millions
The Pennant Group Inc 35.76%$ 35.755 millions
Quanterix Corporation35.42%$ 35.416 millions
Inspiremd Inc 34.88%$ 34.882 millions
The Oncology Institute Inc 34.62%$ 34.624 millions
Agenus Inc34.36%$ 34.358 millions
Biodesix Inc 34.18%$ 34.184 millions
Myomo Inc 33.82%$ 33.819 millions
Ligand Pharmaceuticals Incorporated33.73%$ 33.733 millions
Biocryst Pharmaceuticals Inc 33.61%$ 33.606 millions
Biofrontera Inc 32.92%$ 32.924 millions
Ironwood Pharmaceuticals inc 32.62%$ 32.617 millions
Cadre Holdings inc 32.56%$ 32.561 millions
Supernus Pharmaceuticals inc 32.40%$ 32.399 millions
Corcept Therapeutics Inc31.74%$ 31.743 millions
Establishment Labs Holdings Inc 31.73%$ 31.733 millions
Aclarion Inc 30.48%$ 30.483 millions
Harmony Biosciences Holdings inc 30.42%$ 30.421 millions
Personalis Inc 29.96%$ 29.960 millions
Beone Medicines Ltd 29.69%$ 29.693 millions
Capsovision Inc 29.60%$ 29.598 millions
Intuitive Surgical Inc 29.27%$ 29.272 millions
Xeris Biopharma Holdings Inc 28.74%$ 28.741 millions
Ultragenyx Pharmaceutical Inc 28.53%$ 28.532 millions
Innoviva Inc 28.39%$ 28.391 millions
Electrocore Inc 28.03%$ 28.031 millions


About Adaptive Biotechnologies Revenue Growth Rates (ADPT), Current and Historic Growth - CSIMarket Analysis

How we calculate this

This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years). Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.

Last updated

  • Page updated:
  • Data lineage: SEC filings → XBRL parse → normalization CSIMarket.com Database → growth calculations.
  • Figures are derived from filed reports and may be restated; numbers are subject to revision.

Sources: the company’s SEC filings (XBRL/Inline XBRL) and CSIMarket.com’s normalization & QA processes.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.